Please login to the form below
Wellcome
This page shows the latest Wellcome news and features for those working in and with pharma, biotech and healthcare.
New study identifies gene associated with strong immune response to COVID-19 vaccines
genomic medicine at the university’s Wellcome Centre for Human Genetics and chief investigator of the study. ... Dr Alexander Mentzer, National Institute for Health and Care Research academic clinical lecturer at the Wellcome Centre for Human Genetics
Latest news
-
MHRA and NICE awarded £1.8m to explore regulation of digital mental health tools
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have been awarded £1.8m in funding by Wellcome over three years to ... As a means of providing a solution to this issue,
-
NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia
beginning in childhood,” said Sadaf Farooqi, professor at the Wellcome-MRC Institute of Metabolic Science and the National Institute for Health and Care Research Cambridge Biomedical Research Centre.
-
Researchers create ‘world’s largest’ database for predicting cancer treatment response
Researchers from the Wellcome Sanger Institute and the Children’s Medical Research Institute (CMRI) have created the ‘world’s largest’ database for predicting cancer treatment response based on cancer proteins. ... Mathew Garnett, a senior author
-
ICR scientists create AI test to predict cancer drug combinations
The study has been published in the Molecular Cancer Therapeutics journal, with funding from the National Institute for Health Research (NIHR), Cancer Research UK, Wellcome and the ICR.
-
Parkinson’s UK and Domainex announce new collaboration
Domainex has built up significant expertise of working with several charities and patient foundations, including projects funded by the British Heart Foundation, CHDI Foundation and the Wellcome Trust.
More from news
Approximately 7 fully matching, plus 111 partially matching documents found.
Latest Intelligence
-
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
Ingelheim Foundation, the European Investment Bank and the Wellcome Trust.
-
The global antibiotic crisis: a 2020 perspective
Its report, published in June 2019 in collaboration with the Wellcome Trust, also noted that only 16 new drug candidates targeting high- priority pathogens are now in development, and almost all
-
A snapshot of Microbiotica
Microbiotica’s capability is founded on ground- breaking research from ten years of investment in the microbiome at the Wellcome Sanger Institute. ... In two-and-a-half years we have built an organisation of over 35 people with all the key disciplines
-
2019: CRISPR and therapeutic gene editing comes of age
Meanwhile, earlier this year another group at the Wellcome Sanger Institute found that the technique can cause deletions that are far longer than expected, suggesting that these ‘may have pathogenic consequences’
-
Cutting through the noise: CRISPR
Using CRISPR to identify drug targets. AstraZeneca has collaborated with the Wellcome Sanger Institute, allowing access to its CRISPR libraries.
More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest appointments
-
Henry Skinner has been appointed as the first CEO of the AMR Action Fund
the Wellcome Trust.
-
Neurocentrx appoints two members to the board
Brooksby brings experience in business and growth strategy across the healthcare sector having held senior global positions at Pfizer, Sanofi and Wellcome - now GSK.
-
David Colpman joins Forendo Pharma’s board
His previous roles include head of global business development at Shire and business development and commercial positions at Glaxo Wellcome - now GlaxoSmithKline - and Novo Nordisk.
-
Former Sanofi chairman joins Pertinax Pharma
He has held senior appointments in Wellcome - nowand as chairman and MD at Sanofi UK and Ireland and as a member of the Sanofi Executive Committee in Europe and America.
-
Zyme Communications strengthens team
Prior to Zyme, Ricketts served Axol Bioscience as its science marketing specialist and content writer and has previously worked as a research at the Institute of Cancer Research and Wellcome Trust
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
A magic milestone: Sally’s 10-year #LucidLife workiversary
A colleague left the lab to work in pharma as a Clinical Research Associate (CRA); I followed with a role as a CRA at Wellcome and absolutely loved it.
-
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences
-
Porterhouse enhances its client services and creative teams with a double recruitment
As part of her degree, Catherine worked on a genetics project funded by the Wellcome Trust.
-
Random42 Partner with MedCity for BioJapan 2018
of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world-class research centres including The Francis Crick Institute, Harwell Oxford, and the Wellcome Sanger
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
